Overview

Iparomlimab and Tuvonralimab Combined With Platinum-Based Chemotherapy for Neoadjuvant Treatment of Cervical Cancer

Status:
NOT_YET_RECRUITING

Trial end date:
2026-12-31

Target enrollment:

Participant gender:

Summary

The primary objective of this study is to evaluate the efficacy and safety of Iparomlimab and tuvonralimab (QL1706) in combination with platinum-based chemotherapy for cervical cancer neoadjuvant therapy. Additionally, the study aims to identify potential predictive biomarkers for therapeutic efficacy by analyzing tumor tissues and peripheral blood samples from participants receiving this combined treatment regimen.

Phase:

PHASE2

Details

Lead Sponsor:

Shandong Tumor Hospital

Treatments:

Platinum Compounds